Clinical Pharmacology

The Clinical Pharmacology shared resource at the Masonic Cancer Center provides pharmacology services and expertise for funded cancer-related projects of Masonic Cancer Center members. Investigators are encouraged to contact the Clinical Pharmacology shared resource early in the planning stages of the project to assess feasibility and determine study design.

Publication acknowledgment request

Publication acknowledgment request

The Clinical Pharmacology Shared Resource receives grant support from the National Cancer Institute, which should be acknowledged in any publications. The following statement is suggested: "We would like to acknowledge the assistance of the Clinical Pharmacology Shared Resource of the Masonic Cancer Center, a comprehensive cancer center designated by the National Cancer Institute, supported in part by P30 CA77598."

We would appreciate a reprint of your publications.
We appreciate your acknowledgment of Clinical Pharmacology services in your publications.



Flow chart shows: Research concept, PK/PD/PG study design, proposal preparation, method development, method validation, sample analysis, pharmacokinetic, pharmacodynamic, pharmacogenetic modeling, manuscript preparation


  • Review pharmacology background
  • Pharmacokinetic/pharmacogenetic/pharmacodynamic study design
  • Write pharmacology components of grants and research protocols

Drug and Metabolite Analyses

  • Develop and validate assay methods for sample analysis
  • Human subject biological sample analyses (e.g., blood, plasma, PBMC, tumor)

Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Analyses

  • Pharmacokinetic analyses
  • Pharmacogenetic analyses
  • Pharmacodynamic analyses
  • Results interpretation
  • Author pharmacology components of abstracts, reports, and manuscript(s)

Equipment and analysis examples

Equipment and analysis examples

HPLC equipmentHigh-performance liquid chromatography (HPLC) equipment

Gemcitabine and metabolite concentration time plots

Gemcitabine time plotGemcitabine

Gemcitabine Triphosphate time plotsGemcitabine Triphosphate

Busulfan pharmacogenetics

Post-hoc IV busulfan clearance estimates in patients with GSTA1*A/*A, GSTA1*A/*B and GSTA1*B/*B genotypes. The solid lines represent the means for each genotype.Post-hoc IV busulfan clearance estimates in patients with GSTA1*A/*A, GSTA1*A/*B and GSTA1*B/*B genotypes. The solid lines represent the means for each genotype.



Consultation for study design and feasibility are provided free of charge to researchers planning cancer-related grant applications and research protocols or conducting cancer-related research (pilot and feasibility studies).

Analytical service costs are recovered through percent (%) effort of personnel, supplies and instrument time.

Pharmacokinetic, pharmacodynamic, and pharmacogenetic modeling are provided free of charge for small studies (e.g., Phase I/II).


Mark Kirstein, Pharm.D.
Associate Professor of Clinical Pharmacology
717 Delaware St., S.E., Room 459

Laboratory Manager
Jim Fisher, B.S.
Experimental and Clinical Pharmacology

Video on services provided